Ideaya fast tracked for ovarian cancer treatment

 

• Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with BRCA1/2 mutant advanced or metastatic ovarian cancer who are platinum resistant and have received prior antiangiogenic and PARP inhibitor therapies

• Enables IDE161 development program to access expedited regulatory review processes, including potential eligibility for accelerated approval / priority review

• Ongoing Phase 1 expansion, with focus in ER+, Her2(-), HRD+ breast cancer, HRD+ ovarian cancer and other HRD+ solid tumors, including endometrial and colon cancer

https://finance.yahoo.com/news/ideaya-receives-fast-track-designation-100000970.html